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and lung metastasis. He died 2 months
after surgery. He had wild-type Kras
and EGFR gene. Of 19 thymomas, we
detected only one case with increased
Kras copy number.
Advanced thymic carcinoma is a
very aggressive disease. To date, there
are no established treatment options for
the refractory and recurrent disease, and
few prospective trials were conducted in
patients with thymic carcinoma. Re-
sponses to EGFR tyrosine kinase inhib-
itors have been rare in unselected thy-
mic tumors. Coupled with the data on
Kras and EGFR mutations could explain
the findings. Kras mutations predict for
primary resistance to anti-EGFR thera-
pies, gefitinib/erlotinib in lung cancer,
and cetuximab in colon cancer. These
findings could have therapeutic implica-
tions for the treatment of thymic tumors.
Although Kras mutations or increased
copy number are rare in thymic tumors,
further assessment of Kras is needed
and should be included in any therapeu-
tic trial considering anti-EGFR therapy
for thymic malignancies.
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Leptomeningeal
Metastases from Small
Cell Lung Cancer
Responsive to
Temozolomide
Therapy
To the Editor:
Leptomeningeal spread of small
cell lung cancer (SCLC) is extremely
difficult to treat. Symptoms typically
progress rapidly, and the prognosis is
poor with a median survival of 1.3
months.1 Temozolomide, a nonclassic
oral alkylating agent with penetra-
tion into the central nervous system, is
a standard therapy for glioblastoma
multiforme and refractory astrocy-
toma. Herein, we report two patients
with leptomeningeal metastases from
SCLC who received temozolomide
and had dramatic improvement of their
disease.
PATIENT 1
A 53-year-old man, former 37
pack-year smoker, was diagnosed with
SCLC after presenting with limbic en-
cephalitis. He received six cycles of
etoposide and cisplatin with concur-
rent radiation therapy to the thorax. A
brain metastasis was irradiated and
then resected because of increased
symptoms. Subsequent imaging re-
vealed new brain lesions and plaque-
like leptomeningeal spread. Temozo-
lomide was started at 75 mg/m2 for 21
days of a 28-day cycle and modified to
125 mg/m2 for 5 days because of grade
4 thrombocytopenia. Imaging 10
weeks after starting temozolomide
showed significant interval improve-
ment. Unfortunately, an magnetic res-
onance imaging of the spine 6 weeks
later showed progression.
PATIENT 2
A 61-year-old woman, former 44
pack-year smoker, was diagnosed with
SCLC after presenting with postob-
structive pneumonia. She received five
cycles of carboplatin and etoposide
and radiation to alleviate left main
stem bronchus obstruction. She also
received whole brain radiation for a
lesion on the third ventricle. Imaging 4
months later revealed extensive lepto-
meningeal disease (Figure 1A). She
started temozolomide 150 mg/m2 for 5
days every 21 days. Repeat imaging
after 7.5 weeks showed significant im-
provement (Figure 1B). Follow-up
magnetic resonance imagings showed
maintained response at 6 weeks but
progression at 18 weeks.
For over 40 years, alkylating agents
have demonstrated efficacy in SCLC. Al-
kylators produce specific DNA lesions
that, when left unrepaired, lead to cytotox-
icity and apoptosis. The MGMT (O6-
methyl-guanine-DNA methyltransferase)
gene encodes a DNA-repair protein that
is irreversibly inactivated with each re-
pair of alkylator-induced damage.
Availability of MGMT may therefore be
an important determinant of treatment
failure with alkylators.2 In addition,
methylation of the MGMT promoter
may affect sensitivity to alkylating
agents,2 and aberrant methylation of
MGMT is found in SCLC.
To better characterize temozolo-
mide activity in SCLC, we are conduct-
ing a phase II trial of temozolomide as
second- or third-line therapy for SCLC.
Patients with brain metastases are eligi-
ble but leptomeningeal disease is ex-
cluded because of the poor prognosis.
Preliminary data were presented at the
International Association for the Study
of Lung Cancer meeting in 2009. Of
note, regression of brain metastases in
three patients previously treated with
cranial radiation was observed.3
Herein, we reported the dramatic
responses of SCLC leptomeningeal dis-
ease to temozolomide in two patients.
The responses may not be durable, but
this treatment clearly improved survival
for these patients. Based on these robust
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responses and the preliminary data from
our ongoing trial, we are hopeful that
temozolomide will prove a useful addi-
tion to the arsenal of agents with effi-
cacy in SCLC.
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FIGURE 1. A, Baseline magnetic resonance imaging (MRI) before therapy
with temozolomide shows prominent areas of leptomeningeal disease at T1,
L1–L2, conus medullaris, and cauda equina. B, Restaging MRI 39 days after
initiating temozolomide therapy demonstrates marked contraction of prior
lesions.
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